keyword
MENU ▼
Read by QxMD icon Read
search

Discontinuation of chemotherapy treatment

keyword
https://www.readbyqxmd.com/read/28079002/neurotoxicity-associated-with-platinum-based-anti-cancer-agents-what-are-the-implications-of-copper-transporters
#1
Vanesa Stojanovska, Rachel McQuade, Emma Rybalka, Kulmira Nurgali
Platinum-based anti-cancer agents, which include cisplatin, carboplatin and oxaliplatin, are an important class of drugs used in clinical setting to treat a variety of cancers. The cytotoxic efficacy of these drugs is mediated by the formation of interstrand and intrastrand crosslinks, or platinum adducts on nuclear DNA. There is also evidence demonstrating that mitochondrial DNA is susceptible to platinum-adduct damage in dorsal root ganglia neurons. Although all platinum-based agents form similar DNA adducts, they are quite different in terms of activation, systemic toxicity and tolerance...
January 11, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28078540/preplanned-safety-analysis-of-the-jfmc37-0801-trial-a-randomized-phase-iii-study-of-six-months-versus-twelve-months-of-capecitabine-as-adjuvant-chemotherapy-for-stage-iii-colon-cancer
#2
Takeshi Suto, Megumi Ishiguro, Chikuma Hamada, Katsuyuki Kunieda, Hiroyuki Masuko, Ken Kondo, Hideyuki Ishida, Genichi Nishimura, Kazuaki Sasaki, Takayuki Morita, Shoichi Hazama, Koutarou Maeda, Hideyuki Mishima, Hideyuki Ike, Sotaro Sadahiro, Kenichi Sugihara, Masazumi Okajima, Shigetoyo Saji, Junichi Sakamoto, Naohiro Tomita
BACKGROUND: Six months of adjuvant chemotherapy is regarded as the standard of care for patients with stage III colon cancer. However, whether longer treatment can improve prognosis has not been fully investigated. We conducted a phase III study comparing 6 and 12 months of adjuvant capecitabine chemotherapy for stage III colon cancer, and report here the results of our preplanned safety analysis. METHODS: Patients aged 20-79 years with curatively resected stage III colon cancer were randomly assigned to receive 8 cycles (6 months) or 16 cycles (12 months) of capecitabine (2500 mg/m(2)/day on days 1-14 of each 21-day cycle)...
January 11, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28076611/sarcopenia-and-chemotherapy-mediated-toxicity
#3
Maria Cecília Monteiro Dela Vega, Alessandro Laviano, Gustavo Duarte Pimentel
This narrative review focuses on the role of sarcopenia and chemotherapy-induced toxicity in cancer patients. Consistent evidence shows that sarcopenia in cancer patients leads to decreased overall survival by influencing treatment discontinuation and dose reduction. Therefore, sarcopenia should be considered a robust prognostic factor of negative outcome as well as a determinant of increased healthcare costs. RESUMO Esta revisão narrativa descreve o papel da sarcopenia e a toxicidade mediada pela quimioterapia em pacientes com câncer...
October 2016: Einstein
https://www.readbyqxmd.com/read/28053813/could-adjuvant-chemotherapy-after-surgery-benefit-elderly-patients-with-advanced-gastric-cancer
#4
Jin Woon Jeong, In Gyu Kwon, Young-Gil Son, Seung Wan Ryu
PURPOSE: The aim of this study was to evaluate tolerance to adjuvant chemotherapy, and to compare survival between treatments using only surgery and using surgery with adjuvant chemotherapy, in elderly patients with advanced gastric cancer who were ≥75 years of age. MATERIALS AND METHODS: Patients ≥75 years of age who were diagnosed with pathological stage II or III gastric cancer were identified retrospectively and categorized into the surgery only and surgery with adjuvant chemotherapy groups...
December 2016: Journal of Gastric Cancer
https://www.readbyqxmd.com/read/28050149/treatment-patterns-and-survival-in-patients-with-alk-positive-non-small-cell-lung-cancer-a-canadian-retrospective-study
#5
S Kayaniyil, M Hurry, J Wilson, P Wheatley-Price, B Melosky, J Rothenstein, V Cohen, C Koch, J Zhang, K Osenenko, G Liu
BACKGROUND: Crizotinib was the first agent approved for the treatment of anaplastic lymphoma kinase (ALK)-positive (+) non-small-cell lung cancer (nsclc), followed by ceritinib. However, patients eventually progress or develop resistance to crizotinib. With limited real-world data available, the objective of the present work was to evaluate treatment patterns and survival after crizotinib in patients with locally advanced or metastatic ALK+ nsclc in Canada. METHODS: In this retrospective study at 6 oncology centres across Canada, medical records of patients with locally advanced or metastatic ALK+ nsclc were reviewed...
December 2016: Current Oncology
https://www.readbyqxmd.com/read/28042155/evaluation-of-toxicity-of-a-chronic-alternate-day-metronomic-cyclophosphamide-chemotherapy-protocol-in-dogs-with-naturally-occurring-cancer
#6
Arata Matsuyama, J Paul Woods, Anthony J Mutsaers
Sterile hemorrhagic cystitis (SHC) is an important complication of cyclophosphamide chemotherapy in dogs as it is reported in up to 23% of cases with various protocols. The current study reports toxicities of a protocol of metronomic cyclophosphamide, and identifies risk factors for development of adverse effects. A retrospective cohort study of dogs treated with metronomic cyclophosphamide at an intended dose of 25 mg/m(2) every other day was conducted. Fifty dogs were included with a median length of treatment of 90 days (range: 1 to 1305 days)...
January 2017: Canadian Veterinary Journal. la Revue Vétérinaire Canadienne
https://www.readbyqxmd.com/read/28035312/paclitaxel-associated-reticulate-hyperpigmentation-report-and-review-of-chemotherapy-induced-reticulate-hyperpigmentation
#7
Philip R Cohen
Drug-induced reticulate hyperpigmentation is uncommon. Including the patient described in this report, chemotherapy-associated reticulate hyperpigmentation has only been described in ten individuals. This paper describes the features of a woman with recurrent and metastatic breast cancer who developed paclitaxel-induced reticulate hyperpigmentation and reviews the characteristics of other oncology patients who developed reticulate hyperpigmentation from their antineoplastic treatment. A 55-year-old Taiwanese woman who developed reticulate hyperpigmentation on her abdomen, back and extremities after receiving her initial treatment for metastatic breast cancer with paclitaxel is described...
December 16, 2016: World Journal of Clinical Cases
https://www.readbyqxmd.com/read/28030806/a-phase-1-dose-escalation-study-of-the-oral-histone-deacetylase-inhibitor-abexinostat-in-combination-with-standard-hypofractionated-radiotherapy-in-advanced-solid-tumors
#8
Eric Deutsch, Elizabeth Cohen-Jonathan Moyal, Vanesa Gregorc, Paolo Andrea Zucali, Jean Menard, Jean-Charles Soria, Ioana Kloos, Jeff Hsu, Ying Luan, Emily Liu, Remus Vezan, Thorsten Graef, Sofia Rivera
Current treatments for advanced solid tumors tend to be only palliative. Although radiotherapy is administered with a curative intent, radioresistance and dose-limiting toxicities pose limitations to treatment. Abexinostat, an oral pan-histone deacetylase inhibitor, demonstrated enhanced sensitivity to radiation in various solid tumor cell lines. We conducted an exploratory, phase 1, dose-escalation study of abexinostat in combination with standard hypofractionated radiotherapy in patients with advanced solid tumors treated in a palliative setting...
December 24, 2016: Oncotarget
https://www.readbyqxmd.com/read/28028255/-a-new-treatment-strategy-novel-cell-free-and-concentrated-ascites-reinfusion-system-km-cart-for-massive-malignant-ascites
#9
Keisuke Matsusaki
Massive ascites associated with cancerous peritonitis can result in severe respiratory discomfort and abdominal fullness. Additionally, it can significantly impair the activities of daily living of a patient, and relaxation is difficult to achieve, even with opioids. Frequent ascites drainage can cause rapid worsening of the patient's general condition, and a large amount of ascites can lead to discontinuation of anti-cancer treatment. Cell-free and concentrated ascites reinfusion therapy(CART)for refractory ascites was first covered by the insurance system in 1981...
December 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28007626/risk-of-treatment-related-toxicities-from-egfr-tyrosine-kinase-inhibitors-a-meta-analysis-of-clinical-trials-of-gefitinib-erlotinib-and-afatinib-in-advanced-egfr-mutated-non-small-cell-lung-cancer
#10
Pei Ni Ding, Sarah J Lord, Val Gebski, Matthew Links, Victoria Bray, Richard J Gralla, James Chih-Hsin Yang, Chee Khoon Lee
BACKGROUND: Gefitinib, erlotinib, and afatinib are tyrosine kinase inhibitors (TKIs) used for treatment of advanced epidermal growth factor receptor (EGFR) mutated non-small-cell lung cancer (NSCLC). Estimating differences in toxicity between these EGFR-TKIs is important for personalizing treatment. METHODS: We performed a meta-analysis of randomized trials that compared EGFR-TKI against chemotherapy or placebo. We extracted data from the EGFR-TKI arm for indirect comparisons to estimate the relative risk of toxic death, grade 3-4 (G3/4) adverse events (AEs) and treatment discontinuation due to AE for each EGFR-TKI...
December 19, 2016: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/27998971/a-phase-i-ii-study-of-cancer-peptide-vaccine-s-288310-in-patients-with-advanced-urothelial-carcinoma-of-the-bladder
#11
W Obara, M Eto, H Mimata, K Kohri, N Mitsuhata, I Miura, T Shuin, T Miki, T Koie, H Fujimoto, K Minami, Y Enomoto, T Nasu, T Yoshida, H Fuse, I Hara, K Kawaguchi, A Arimura, T Fujioka
BACKGROUND: S-288310, a cancer peptide vaccine composed of two HLA-A*24:02-restricted peptides derived from two oncoantigens, DEP domain-containing 1 (DEPDC1) and M-phase phosphoprotein 1 (MPHOSPH1), was investigated in urothelial carcinoma (UC) of the bladder. PATIENTS AND METHODS: Thirty eight HLA-A*24:02-positive patients with progressive UC were enrolled in this study. In the phase I part of the study, three patients each were treated with S-288310 at 1 mg or 2 mg/peptide subcutaneously once a week to evaluate safety and tolerability...
December 20, 2016: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/27992451/phase-i-ii-trial-of-sorafenib-in-combination-with-vinorelbine-as-first-line-chemotherapy-for-metastatic-breast-cancer
#12
Cristiano Ferrario, Ivan Strepponi, Khashayar Esfahani, Helen Charamis, Adrian Langleben, Emanuela Scarpi, Oriana Nanni, Wilson H Miller, Lawrence C Panasci
BACKGROUND: Preclinical models have reported a synergistic interaction between sorafenib and vinorelbine. We investigated the toxicity, efficacy, and pharmacokinetics interaction of this combination as first-line treatment for patients with metastatic breast cancer. METHODS: Patients were HER2-negative and treated with vinorelbine 30 mg/m2 IV days 1,8 every 21 plus daily oral sorafenib. In the phase I portion (3+3 design) patients received sorafenib 200 mg BID (cohort 1) or 400 mg BID (cohort 2)...
2016: PloS One
https://www.readbyqxmd.com/read/27987584/corneal-graft-rejection-in-a-patient-treated-with-nivolumab-for-primary-lung-cancer
#13
S Le Fournis, P Gohier, T Urban, T Jeanfaivre, J Hureaux
We report the case of a 58-year-old woman treated with nivolumab for an unresectable squamous non-small cell lung cancer, after first-line cisplatin and gemcitabine combination chemotherapy. This woman had a history of left corneal graft. After 9 cycles of nivolumab, the patient described decreased visual acuity in the left eye with watering and conjunctival erythema. Ophthalmological examination revealed chronic corneal graft rejection. The patient was then treated with an intravenous bolus of corticosteroids (500mg of methylprednisolone) for 3 days, followed by oral prednisone for 4 weeks and subconjunctival corticosteroid injections every 48h, while treatment with nivolumab was discontinued...
December 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27981793/responses-to-romidepsin-by-line-of-therapy-in-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphoma
#14
Francine Foss, Barbara Pro, H Miles Prince, Lubomir Sokol, Dolores Caballero, Steven Horwitz, Bertrand Coiffier
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas typically associated with poor prognosis. Most patients with PTCL receive chemotherapy as first-line treatment, but many experience rapid relapse. For patients with relapsed/refractory PTCL, responses to treatment and long-term outcomes tend to worsen with increasing lines of therapy. Romidepsin is a potent class I histone deacetylase inhibitor approved by the US Food and Drug Administration for the treatment of PTCL in patients who have received ≥1 prior therapy...
December 16, 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27978579/effect-of-selumetinib-and-mk-2206-vs-oxaliplatin-and-fluorouracil-in-patients-with-metastatic-pancreatic-cancer-after-prior-therapy-swog-s1115-study-randomized-clinical-trial
#15
Vincent Chung, Shannon McDonough, Philip A Philip, Dana Cardin, Andrea Wang-Gillam, Laifong Hui, Mohamedtaki A Tejani, Tara E Seery, Irene A Dy, Tareq Al Baghdadi, Andrew E Hendifar, L Austin Doyle, Andrew M Lowy, Katherine A Guthrie, Charles D Blanke, Howard S Hochster
Importance: KRAS mutations are common in pancreatic cancer, but directly targeting the KRAS protein has thus far been unsuccessful. The aim of this trial was to block the MEK and PI3K/AKT pathways downstream of the KRAS protein as an alternate treatment strategy to slow cancer growth and prolong survival. This was the first cooperative group trial to evaluate this strategy using molecularly targeted oral combination therapy for the treatment of chemotherapy-refractory pancreatic cancer...
December 15, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27965838/immediate-tumor-resection-in-patients-with-locally-advanced-gastroesophageal-adenocarcinoma-with-nonresponse-to-chemotherapy-after-4%C3%A2-weeks-of-treatment-versus-resection-after-completion-of-chemotherapy-optitreat-trial-drks00004668-study-protocol-for-a-randomized
#16
Susanne Blank, Phillip Knebel, Georg-Martin Haag, Thomas Bruckner, Ulla Klaiber, Maria Burian, Anja Schaible, Leila Sisic, Thomas Schmidt, Markus K Diener, Katja Ott
BACKGROUND: Neoadjuvant chemotherapy is a standard of care for patients with adenocarcinoma of the esophagus and stomach in Europe, but still only 20-40 % respond to therapy and the critical issue; how to treat nonresponding patients is still unclear. So far, there is no randomized trial evaluating the impact of early termination of neoadjuvant chemotherapy and immediate tumor resection in nonresponding patients with locally advanced gastroesophageal cancer on postoperative outcome. With this exploratory pilot trial, we want to get first estimates about the effect of discontinuation of chemotherapy with the aim to plan and conduct a further definitive trial...
2016: Pilot and Feasibility Studies
https://www.readbyqxmd.com/read/27956157/ibrutinib-for-patients-with-rituximab-refractory-waldenstr%C3%A3-m-s-macroglobulinaemia-innovate-an-open-label-substudy-of-an-international-multicentre-phase-3-trial
#17
Meletios A Dimopoulos, Judith Trotman, Alessandra Tedeschi, Jeffrey V Matous, David Macdonald, Constantine Tam, Olivier Tournilhac, Shuo Ma, Albert Oriol, Leonard T Heffner, Chaim Shustik, Ramón García-Sanz, Robert F Cornell, Carlos Fernández de Larrea, Jorge J Castillo, Miquel Granell, Marie-Christine Kyrtsonis, Veronique Leblond, Argiris Symeonidis, Efstathios Kastritis, Priyanka Singh, Jianling Li, Thorsten Graef, Elizabeth Bilotti, Steven Treon, Christian Buske
BACKGROUND: In the era of widespread rituximab use for Waldenström's macroglobulinaemia, new treatment options for patients with rituximab-refractory disease are an important clinical need. Ibrutinib has induced durable responses in previously treated patients with Waldenström's macroglobulinaemia. We assessed the efficacy and safety of ibrutinib in a population with rituximab-refractory disease. METHODS: This multicentre, open-label substudy was done at 19 sites in seven countries in adults aged 18 years and older with confirmed Waldenström's macroglobulinaemia, refractory to rituximab and requiring treatment...
December 9, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27955684/safety-and-efficacy-of-vinorelbine-in-combination-with-pertuzumab-and-trastuzumab-for-first-line-treatment-of-patients-with-her2-positive-locally-advanced-or-metastatic-breast-cancer-velvet-cohort-1-final-results
#18
Edith A Perez, José Manuel López-Vega, Thierry Petit, Claudio Zamagni, Valerie Easton, Julia Kamber, Eleonora Restuccia, Michael Andersson
BACKGROUND: Pertuzumab, trastuzumab, and docetaxel is standard of care for first-line treatment of HER2-positive metastatic breast cancer (MBC). However, alternative chemotherapy partners are required to align with patient/physician preferences and to increase treatment flexibility. We report VELVET Cohort 1 results in which the efficacy and safety of pertuzumab and trastuzumab, administered sequentially in separate infusions, followed by vinorelbine, were evaluated. Cohort 2, where pertuzumab and trastuzumab were administered in a single infusion, followed by vinorelbine, recruited after Cohort 1 was fully enrolled, will be reported later...
December 13, 2016: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/27942221/a-randomized-phase-ii-trial-of-the-tumor-vascular-disrupting-agent-ca4p-fosbretabulin-tromethamine-with-carboplatin-paclitaxel-and-bevacizumab-in-advanced-nonsquamous-non-small-cell-lung-cancer
#19
Edward B Garon, Jeffrey D Neidhart, Nashat Y Gabrail, Moacyr R de Oliveira, Jai Balkissoon, Fairooz Kabbinavar
INTRODUCTION: Combretastatin A4-phosphate, fosbretabulin tromethamine (CA4P) is a vascular disrupting agent that targets tumor vasculature. This study evaluated the safety of CA4P when combined with carboplatin, paclitaxel, and bevacizumab in chemotherapy-naïve subjects with advanced nonsquamous, non-small-cell lung cancer. METHODS: Adult subjects with confirmed American Joint Committee on Cancer six stage IIIB/IV non-small-cell lung cancer and an Eastern Cooperative Oncology Group performance score of 0 or 1 were randomized to receive six cycles (treatment phase) of paclitaxel (200 mg/m(2)), carboplatin (area under the concentration versus time curve 6), and bevacizumab (15 mg/kg) on day 1 and repeated every 21 days, or this regimen plus CA4P (60 mg/m(2)) on days 7, 14, and 21 of each cycle...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27939400/atezolizumab-as-first-line-treatment-in-cisplatin-ineligible-patients-with-locally-advanced-and-metastatic-urothelial-carcinoma-a-single-arm-multicentre-phase-2-trial
#20
Arjun V Balar, Matthew D Galsky, Jonathan E Rosenberg, Thomas Powles, Daniel P Petrylak, Joaquim Bellmunt, Yohann Loriot, Andrea Necchi, Jean Hoffman-Censits, Jose Luis Perez-Gracia, Nancy A Dawson, Michiel S van der Heijden, Robert Dreicer, Sandy Srinivas, Margitta M Retz, Richard W Joseph, Alexandra Drakaki, Ulka N Vaishampayan, Srikala S Sridhar, David I Quinn, Ignacio Durán, David R Shaffer, Bernhard J Eigl, Petros D Grivas, Evan Y Yu, Shi Li, Edward E Kadel, Zachary Boyd, Richard Bourgon, Priti S Hegde, Sanjeev Mariathasan, AnnChristine Thåström, Oyewale O Abidoye, Gregg D Fine, Dean F Bajorin
BACKGROUND: First-line chemotherapy for patients with cisplatin-ineligible locally advanced or metastatic urothelial carcinoma is associated with short response duration, poor survival, and high toxicity. This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urothelial cancer in cisplatin-ineligible patients. METHODS: For this single-arm, multicentre, phase 2 study, in 47 academic medical centres and community oncology practices in seven countries in North America and Europe, we recruited previously untreated patients with locally advanced or metastatic urothelial cancer who were cisplatin ineligible...
December 7, 2016: Lancet
keyword
keyword
31212
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"